US 11,110,087 K1 (3,895th)
	Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
Deepak Sampath; Christian Klein; Wayne John Fairbrother; Sari L. Heitner Enschede; Rod A. Humerickhouse; Andrew W. Roberts; and John F. Seymour
Assigned to ABBVIE INC.
Trial No. IPR2023-00052, Oct. 14, 2022
Inter Partes Review Certificate for Patent 11,110,087, issued Sep. 7, 2021, Appl. No. 17/187,468, Feb. 26, 2021
Inter Partes Review Certificate issued Feb. 24, 2025